semaglutide and pots A newly published case series reports that GLP-1 receptor agonists (like semaglutide Pots Weight Loss: Practical Strategies

One study reported that the scaffold protein phosphatidylethanolamine binding protein 1 (PEBP1) binds to 15-lipoxygenase (15LOX) and directs it to PUFAs in the membrane, thereby facilitating ferroptosis [81]

It was applied as a topical spray a simple, non-invasive daily application

Baker WL, Buckley LF, Kelly MS, Bucheit JD, Parod ED, Brown R, et al

Safety Concerns Documented risks include: Contamination risk with multiple pen entries Dosing errors more likely with complex regimens 55% of microdosers self-medicate without medical supervision Use of non-FDA approved compounded formulations 22% regret rate among microdosers Mathematical Modeling: What the Numbers Say Pharmacokinetic Simulations Recent mathematical models using real-world pharmacokinetic data reveal: *Theoretical efficacy based on area under curve (AUC) maintenance Key Modeling Insights Diminishing returns: Daily dosing provides minimal additional benefit over 3x weekly Efficacy threshold: Models suggest 75% efficacy retention even with daily microdosing Individual variation: Fast metabolizers may benefit more from split dosing Dose adjustment needed: Total weekly dose may need 10-20% increase with microdosing Open-source availability: Researchers have made pharmacokinetic models publicly available at GitHub (seanlawley/glp1) for those interested in exploring dosing optimization strategies